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most important to this report, wound dehiscence (Braghiroli et al.,
2012). The majority of wound-healing complications following
bevacizumab have been reported early in the post-operative course,
with few complications documented long after surgical intervention
(Deshaies et al., 2010).
To our knowledge, this is the ﬁrst report of vaginal cuff eviscera-
tion at eight plus months post cytoreduction surgery for ovarian
carcinoma soon after initiation of antiangiogenic therapy.Case reportIntroduction
Novel developments in treatment have improved the 5-year
survival rate for women diagnosed with epithelial ovarian cancer. In
addition to standard surgical cytoreduction and platinum/taxane che-
motherapy, bevacizumab has recently been demonstrated to improve
the progression-free survival rate in patients with ovarian cancer
(Burger et al., 2011). Bevacizumab is a humanized monoclonal anti-
body that binds to vascular endothelial growth factor A (VEGF-A),
blocks the interaction with its receptor, and effectively alters angio-
genesis (Braghiroli et al., 2012). Bevacizumab is thought to normalize
hyperpermeable intratumoral blood vessels thereby increasing the
delivery of simultaneously administered cytotoxic agents and, after
continued treatment, collapsing these vessels (Martin and Schilder,
2007; Jain, 2005). Bevacizumab as a single agent has approximately
a 20% response rate in recurrent ovarian cancer (Burger et al., 2007;
Cannistra et al., 2007). This activity is among the highest for any
cancer, and is probably because normal ovarian tissue is already
primed to respond to VEGF for follicle maturation as well as growth
and formation of the corpus luteum (Martin and Schilder, 2007).
Although generally well tolerated, bevacizumab has a number of
side effects including hypertension, arterial/venous thromboembolicrms of the Creative Commons
which permits non-commercial
d the original author and source
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Skwara).
blished by Elsevier Inc. All rights reWe report on a 44 year old patient who was referred to our
services in November 2010.
Prior to referral, the patient was identiﬁed as having a large
multicystic heterogeneous right adenexal mass and a small left sided
lesion, for which she underwent a laparoscopic bilateral salpingo-
oophorectomy. The pathology showed the right and left ovary to be
involved with a high-grade, poorly differentiated, mixed epithelial
ovarian cancer with both clear cell and endometrioid adenocarcinoma
histologies; the right ovary was fragmented and the left ovarian
capsule intact. Peritoneal washings were negative and endometriosis
was also identiﬁed. Post-operatively, she had a CA-125 level of
284 units/ml.
The patient was referred to our service and underwent an explor-
atory laparotomy, debulking, lysis of adhesions, hysterectomy, resec-
tion of a benign right lobe hepatic lesion, resection of a pelvic tumor
at the posterior vaginal wall, pelvic peritoneotomy, omentectomy, ap-
pendectomy, pelvic, para-aortic, and common iliac bilateral lymph
node dissection, and staging for ovarian carcinoma. At completion,
there was no gross evidence of any disease and the ﬁnal pathology
conﬁrmed FIGO stage IIC mixed epithelial ovarian carcinoma.
Subsequently, the patient was treated with six cycles of both in-
travenous and intraperitoneal chemotherapy, which was completed
on April 4, 2011. At this time, the patient was examined and found
to have a new ﬁrm right vaginal apex lesion suspicious for persistent
disease with a CA-125 of 104 units/ml. She was then placed on
bevacizumab for a total of 4 cycles and had a complete resolution of
this nodular area with a CA-125 level returning to normal limits at
21 units/ml. Her last dose of bevacizumab was given on July 14, 2011.
By history, the patient had intercourse for the ﬁrst time post-
operatively on July 31, 2011, which she reported to be extremelyserved.
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panied by a vaginal discharge. She was examined on August 2, 2011
and found to have complete dehiscence of the vaginal apex with
small bowel evisceration into the upper vagina. The patient's vagina
was packed, a foley catheter inserted, and she was emergently admit-
ted to the hospital. She was then brought into the operating room for
reduction of the small bowel evisceration (Fig. 1), repair of the
vaginal apex with left rectus abdominal muscle ﬂap reinforcement
of this repair (Figs. 2 and 3), and placement of an On-Q ball pain sys-
tem (Tobin et al., 1990). Peritoneal washings were obtained with
pathology showing highly atypical cells present in a background of
acute inﬂammation. The surgery was well tolerated. Bevacizumab was
discontinued and the patient was placed on maintenance albumin-
bound paclitaxel every three weeks for one year. She currently has no
signs of disease with a most recent CA-125 of 13 units/ml (normal
range b35). Upon physical examination all surgical incisions, including
the vaginal apex, are well healed.
Discussion
Antiangiogenic therapy is known to directly result in a number of
adverse reactions, including wound-healing complications. For this
reason, bevacizumab is typically added to platinum/taxane chemo-
therapy at cycle 2 of adjuvant therapy to reduce the risk of dehis-
cence. Most reported bevacizumab-related wound complications in
patients with ovarian cancer are in women recently in the postoper-
ative period (Burger et al., 2011; Koskas et al., 2010). However,
even after a signiﬁcant period of time from surgery prior to
bevacizumab administration, there have been reports of wound com-
plications; most involving bowel perforation and some occurring as
long as 78 months after surgical intervention (Deshaies et al., 2010;Fig. 1. Allis clamps on vaginal apex following reduction of the small bowel evisceration
and prior to the vaginal cuff repair.
Fig. 2. Vaginal cuff repair using #0 Polydioxanone (PDS) sutures.Eveno et al., 2011). In all of these cases, the correlation between
bevacizumab administration and the wound complication seems to
implicate the antiangiogenic compound as the causative agent.
Here, we report on an unusual manifestation of this problem in a
woman experiencing wound dehiscence and evisceration at the
vaginal apex after 4 cycles of bevacizumab and 8+ months postoper-
atively. Because of the unusually long time span between surgical
intervention and wound complication, it is likely, as there were no
other risk factors so far removed from surgery other than the admin-
istration of bevacizumab, that the administered bevacizumab is the
most likely cause.
Recent reports show that bevacizumab induces a vessel “normali-
zation window,” decreasing hypoxia initially and allowing for the
enhanced delivery of additional chemotherapeutics (Winkler et al.,
2004). However, these effects wane with time, increasing hypoxia
and ischemia within the solid tumor, and eventually leading to
increased necrosis of the treated tissue. Since the patient's recurrent
tumor had developed in an area nearby or possibly involving the
former surgical wound at the vaginal cuff, potentially necrotic residual
areas at the wound site following treatment with bevacizumab may
have led to the vaginal wound dehiscence and subsequent bowel
evisceration.
A surgical wound can take up to two years to heal completely with
a maximal strength of only 80% of the original tissue even in the
absence of wound healing impediments (Tibbs, 1997). This healing
process is deﬁned by inﬂammation, proliferation, and maturation.
The inﬂammatory phase occurs during the ﬁrst three days post oper-
atively and includes the formation of the ﬁbrin clot, migration of
neutrophils, macrophages, and monocytes, and the enhancement of
angiogenesis by macrophage derived VEGF-A (Willenborg et al.,
2012). The proliferative phase occurs two days to three weeks post
Fig. 3. Left rectus muscle ﬂap reinforcement of the vaginal cuff repair.
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whereas the maturation phase includes an increase in collagen con-
tent and tensile strength beginning during the proliferative phase
and continuing until the wound is completely healed. It is thought
that anastamotic leaks and ascites may delay the healing process by
halting wound repair in the inﬂammatory and proliferative phases,
a time when VEGF-A production by monocytes/macrophages is at
its peak (Deshaies et al., 2010; Koskas et al., 2010; Willenborg et al.,
2012). Although there were no clinical signs of ascites evident in
this patient, the lack of lymph nodes along her pelvic ﬂoor post-
resection could have lead to greater accumulation of ﬂuid and poten-
tially delayed vaginal cuff healing (Gmyrek et al., 2011). The vaginal
cuff may have thereby been more susceptible to dehiscence following
treatment with bevacizumab due to the increased presence of VEGF-A
during the inﬂammatory and proliferative stages. This increase in
susceptibility, in combination with bevacizumab's necrotic effect on
the patient's solid tumor may very well have led to the complete
dehiscence of the vaginal apex and subsequent evisceration.
Vaginal cuff dehiscence as a complication of total abdominal hys-
terectomy occurs rarely (reported incidence up to 0.26%) (Cronin et
al., 2012). Risk factors include increased age, chronic cough, vaginal
cuff infection and/or hematoma, a greater number of vaginal surgeries,
and vaginal atrophy (Cronin et al., 2012). In concordance with this
report, other factors associated with poor wound healing and
dehiscence include malnutrition, tissue radiation, chronic steroid use,
and malignancy. There is a great deal of variability in the timing of
reported vaginal cuff dehiscence, ranging from 3 days to 30 years post
operatively. Over 70% of such cases have been reported to occur sponta-neously; others have occurred with precipitating events such as
valsalva, strained defecation, and, as in the case of this patient, inter-
course (Cronin et al., 2012). Intercourse is likely to have been the trigger
via trauma to a predisposed scar and surrounding tissue that was
primed by exposure to bevacizumab resulting in deterioration of the
vaginal cuff and subsequent bowel evisceration.
Conclusion
Antiangiogenic agents, such as bevacizumab, can result in wound
healing complications even when primary administration occurs
long after surgical intervention. The surgical wound at the vaginal
apex was expected to be sufﬁciently healed at eight months, making
this complication unanticipated. Although antiangiogenic drugs do
not appear to be harmful to fully healed wounds, when metastases
occur at a surgical site and/or a surgical site has the potential for
chronic inﬂammation, the hypoxia that these agents induce may re-
sult in unexpected complications. In patients that meet these criteria,
physicians should practice with a higher index of suspicion to avoid a
possible life-threatening situation.
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